Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 259

Results For "AI"

8746 News Found

Sanjivani Paranteral posts Q4 FY25 at Rs. 2.19 Cr
News | May 28, 2025

Sanjivani Paranteral posts Q4 FY25 at Rs. 2.19 Cr

For FY25, Revenue from operation grew 28.8 per cent YoY to Rs. 70.1 crore


Fluor-built Bayer cell therapy facility in California achieves LEED v4 platinum certification
News | May 28, 2025

Fluor-built Bayer cell therapy facility in California achieves LEED v4 platinum certification

Facility also named 2025 ISPE Facility of the Year Winner for Social Impact - Unmet Medical Needs


Aurobindo Pharma Q4 PAT falls marginally to Rs. 903 Cr
News | May 27, 2025

Aurobindo Pharma Q4 PAT falls marginally to Rs. 903 Cr

During the quarter, US formulations revenue increased by 13.5 per cent YoY to Rs. 4,072 crore


Sun Pharma Q4 FY25 revenue up 8.5% to Rs. 12,815 Cr
News | May 27, 2025

Sun Pharma Q4 FY25 revenue up 8.5% to Rs. 12,815 Cr

Net profit for the?quarter came in at Rs. 2,889.1 crore, up 4.8 per cent from the year earlier, adjusted for exceptional items


Akums reports Q4 FY25 with 12.4% revenue growth
News | May 27, 2025

Akums reports Q4 FY25 with 12.4% revenue growth

Akums invested Rs. 272 crore in capital expenditure during FY25


Kilitch Drugs posts consolidated Q4 FY25 PAT at Rs. 10.21 Cr
News | May 26, 2025

Kilitch Drugs posts consolidated Q4 FY25 PAT at Rs. 10.21 Cr

The company recorded its quarterly consolidated revenue from operations at Rs. 61.22 crore in Q4 FY25


Torrent Pharma reports Q4 FY25 PAT at Rs. 498 Cr
News | May 26, 2025

Torrent Pharma reports Q4 FY25 PAT at Rs. 498 Cr

The revenue witnessed a growth of 7.80 per cent on a year-on-year basis at Rs. 2,959 crore


Gland Pharma Q4 FY25 PAT falls to Rs. 186.5 Cr
News | May 26, 2025

Gland Pharma Q4 FY25 PAT falls to Rs. 186.5 Cr

R&D spend for Q4 was Rs. 50.3 crore, 4.9 per cent of Q4?revenue


Divi's Laboratories inks manufacturing and supply agreement with global pharma company
News | May 26, 2025

Divi's Laboratories inks manufacturing and supply agreement with global pharma company

The company expects meaningful revenue contribution from this long-term agreement